कृपया अन्य खोज का प्रयास करें
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Sudhir Agrawal | 69 | - | Member of Scientific Advisory Board |
Robert H.I. Andtbacka | - | - | Member of Scientific Advisory Board |
James Patrick Allison | - | 2019 | Member of Scientific Advisory Board |
Aurelien Marabelle | - | - | Member of Scientific Advisory Board |
Kjetil Hestdal | 63 | 2021 | Non-Executive Independent Director |
Jayson M. Rieger | 47 | 2021 | Non-Executive Independent Director |
Brynjar Kristian Forbergskog | 65 | 2021 | Non-Executive Independent Director |
Sandra Demaria | - | - | Member of Scientific Advisory Board |
Marie Ann Roskrow | - | 2023 | Chairperson |
Padmanee Sharma | - | 2019 | Member of Scientific Advisory Board |
Evelina Vagesjo | - | 2021 | Non-Executive Independent Director |
Marie-Louise Helena Fjallskog | 60 | 2021 | Interim CMO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है